Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra (PEN) reported stronger Q3 results with revenue of $354.7 million, up from $301.0 million a year ago, and net income of $45.9 million versus $29.5 million. Operating income rose to $48.8 million from $35.4 million as gross profit increased to $240.4 million. Thrombectomy contributed $236.4 million and Embolization & Access $118.3 million. U.S. sales were $275.0 million and international $79.7 million.
For the first nine months, revenue reached $1,018.3 million (from $879.1 million) and net income was $130.3 million compared to a loss of $19.7 million last year. Cash and cash equivalents were $321.0 million, with $149.3 million in marketable investments, and operating cash flow of $152.2 million year‑to‑date. The company is building a ~330,000 sq. ft. Costa Rica facility, expecting about $35 million in project costs plus $23 million of improvements; $28.3 million was paid through Q3. The board extended the remaining $100.0 million share repurchase authorization to December 31, 2025. The prior immersive healthcare wind‑down carried no new charges in 2025.
Penumbra, Inc. furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and incorporated by reference.
The information was furnished, not filed, and is not subject to Section 18 of the Exchange Act, nor incorporated into other filings unless specifically referenced. The report was signed by CFO Maggie Yuen on November 5, 2025.
Penumbra, Inc. (PEN): Notice of proposed sale under Rule 144. A holder filed to sell 186 shares of Penumbra common stock through Fidelity Brokerage Services LLC, with an aggregate market value $42,329.88. The shares are listed on the NYSE, with an approximate sale date of 11/04/2025.
The securities to be sold were acquired on 09/30/2025 as a stock award from Penumbra in the amount of 186 shares. As context, Penumbra reported 38,999,129 shares outstanding. The filer also reported sales in the prior three months: 186 shares on 09/02/2025 for $50,627.34 and 186 shares on 10/02/2025 for $46,241.46.
Penumbra (PEN) reported an insider transaction by its President, Shruthi Narayan. On 10/15/2025, 1,294 shares of common stock were withheld at $252.61 per share to satisfy tax withholding obligations tied to the vesting of restricted stock units.
Following the transaction, the reporting person beneficially owned 26,961 shares directly. The filing notes that a portion of these shares is subject to vesting.
Penumbra (PEN) director Harpreet Grewal reported a sale of common stock. On 10/02/2025, the reporting person sold 186 shares at $248.61 per share under a Rule 10b5-1 trading plan. Following the transaction, the filer directly beneficially owned 8,702 shares. A portion of these shares is subject to vesting.
Johanna Roberts, EVP, General Counsel & Secretary of Penumbra Inc (PEN), reported multiple open-market sales executed 10/01/2025 under a Rule 10b5-1 trading plan. The transactions total 600 shares sold in separate blocks at weighted-average prices reported per block (ranging across the disclosures). Following these disposals, Ms. Roberts' beneficial ownership is reported as 64,257 shares. The Form 4 is signed and dated 10/03/2025. The filing notes that a portion of the shares sold were subject to vesting and that the filer will provide trade-level details upon request.
Penumbra Inc. (PEN) director Thomas C. Wilder reported a sale of 186 shares of common stock on 10/01/2025 at a price of $253.93 per share. The filing states the sale was executed under the reporting person’s Rule 10b5-1 trading plan. After the sale the report shows the reporting person beneficially owns 186 shares directly and 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006. The filing also notes that a portion of the reported shares are subject to vesting.
The Form 4 was signed by an attorney-in-fact on behalf of Mr. Wilder on 10/03/2025. No options, derivative transactions, earnings figures, or other corporate actions are disclosed in this form; it records a single small open-market sale and the current direct and indirect holdings disclosed by the reporting person.
Form 144 filed for Penumbra, Inc. (PEN) reports a proposed sale of 186 shares of Common Stock through Fidelity Brokerage Services LLC (Boston, MA) with an aggregate market value of $46,241.46 and an approximate sale date of 10/02/2025. The shares were acquired as a stock award from Penumbra, Inc. on 06/30/2025. The filer also reported a sale of 186 shares on 09/02/2025 with gross proceeds of $50,627.34. The filing names the seller as Grewal Harpreet (c/o Penumbra).
Form 144 notice for Penumbra, Inc. (PEN) reporting proposed sale of common stock. The filing shows 1,800 shares to be sold through J.P. Morgan Securities LLC with an aggregate market value of 455,796, and the approximate sale date listed as 10/01/2025 on the NYSE. The shares were acquired on 12/28/2022 by option exercise and paid in cash. The filer recorded prior sales in the past three months: 600 shares on 08/11/2025 for 143,361.60 and 600 shares on 09/02/2025 for 162,345.63. The filing includes a representation that the seller does not possess undisclosed material adverse information.
Penumbra, Inc. (PEN) filing under Rule 144 notifies the market that a person for whose account securities are being sold intends to sell 186 shares of common stock through Morgan Stanley Smith Barney LLC on or about 10/01/2025. The filing lists the aggregate market value of the shares to be sold as $47,230.98 based on the reported market price, and shows total shares outstanding of 38,999,129. The 186 shares were acquired as restricted stock from the issuer on 09/30/2025, with payment not applicable. The filer also reported a prior sale on 08/12/2025 of 372 shares that generated gross proceeds of $89,339.52. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
